Song 2018.

Methods	Study design: Randomised clinical trial Study duration: January 2016 to January 2017 Duration of follow‐up: 6 months Setting: Hospital
Participants	Age (mean ± SD, range): TACE + MWA: 53.01 ± 4.54 years; TACE alone: 53.64 ± 3.65 years Male (n/total): TACE + MWA: 19/24; TACE alone: 20/24
Interventions	TACE + MWA group (n = 24): TACE: Chemotherapeutic drugs: epirubicin 20‐80 mg and oxaliplatin 100‐150 mg. One to three sessions of TACE were performed for each patient. MWA: The interval between TACE and MWA was 2‐4 weeks. Output power of 40‐60 W, 15‐20 minutes per MWA session TACE group (n = 24): Chemotherapeutic drugs: epirubicin 20‐80 mg and oxaliplatin 100‐150 mg. One to three sessions of TACE were performed for each patient.
Outcomes	Tumour response Survival rate at 0.5 year after treatment Serum level of AFP
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.